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Introduction
Premature ovarian insufficiency (POI), characterized by a 
loss of function of the ovaries before the age of 40 years 
(1), is a health problem in women that affects 1% of the 
population (2). The spontaneous pregnancy rate is low in 
POI, and although approximately 5–10% of women with 
POI are still able to conceive, most women with POI have 
a permanent loss of fertility. The association between POI 
and rare genetic disorders, some autoimmune and viral 
diseases, chemotherapy, and radiotherapy are well known. 
However, the underlying mechanism is still unknown. It has 
been speculated that there might be a relationship between 
POI and BRCA1 and BRCA2 gene mutations (3–5). There are 
a limited number of studies in the literature on single cases 
or related to small patient groups investigating BRCA1 and 
BRCA2 mutations in patients with premature ovarian insuf-
ficiency.
BRCA1 and BRCA2 genes are responsible for DNA repair. 
Mutations in these genes result in unrepaired DNA damage, 
leading the cell to apoptosis (6). Loss of function in BRCA 
genes in oocytes also leads them to the apoptotic pathway and 
may cause early depletion of ovarian reserves (4). Although the 
association between BRCA1 and BRCA2 gene mutations and 
breast, ovarian, and prostate cancer is clearer, there is insuf-
ficient data concerning POI. Recently, it has been speculated 
that there might be a relationship between POI and BRCA1 and 
BRCA2 gene mutations (5). Although BRCA1 and BRCA2 genes 
have been analyzed in several studies in Turkish population, 
these studies only analyzed the relationships of BRCA1 and 
BRCA2 gene variations and breast cancer (7-9).
Next-generation sequencing is a valuable tool that analyzes 
up to gigabases of DNA reads at a high speed and with a 
low cost per base. This method has also been used in 
worldwide collaborative projects, such as the International 
Genome Consortium (ICGC) (10) and The Cancer Genome 
Atlas (TTGA) (http://cancergenome.nih.gov). Because of the 
large size of BRCA1 and BRCA2 genes (5592 bp and 10257 
bp, respectively) and lack of mutation hot spots, these genes 
need useful prescreening strategies, such as next-generation 
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sequencing; therefore, we used the MiSeq Illumina sequencer 
(MiSeq, Illumina Inc.; San Diego, CA, USA) to detect the variants 
of BRCA1 and BRCA2 genes.
There are only a limited number of studies about the impor-
tance of BRCA1 and BRCA2 gene mutations in the etiology 
of POI in the literature. Therefore, the association of POI and 
BRCA1 and BRCA2 gene mutations is unclear. In the case of 
detecting variations related to breast-ovarian cancer, these 
patients might be referred for screening and follow-up pro-
grams for breast/ovarian cancer before the age of 40 years. 
Hence, we aimed to investigate the role of BRCA1 and BRCA2 
gene mutations in the etiology of POI. According to our knowl-
edge, this study is the first study in Turkish patients to assess 
the genetic predisposition to premature ovarian failure. Also, it 
is the first study to analyze the whole BRCA1 and BRCA2 genes 
by next-generation sequencing in Turkish patients.
Material and Methods
To determine the mutations and variants in the target exon 
sequences of BRCA1 and BRCA2, we sequenced and analyzed 
these genes using next-generation sequencing technology in 
Turkish patients with premature ovarian failure and in control 
subjects.
Patients
We enrolled 101 individuals referred to the Zekai Tahir Burak 
Women’s Health Training and Research Hospital who fulfilled 
the exclusion and inclusion criteria and who accepted to 
participate in our study. The study group consisted of 56 indi-
viduals who had been referred to the IVF unit due to infertility 
problems and who were younger than 40 years of age with an 
antral follicle count <3-5 and FSH levels >12 IU/I. The control 
group consisted of 45 individuals who had been referred to 
the Family Planning Unit due to contraception and who had 
spontaneous pregnancies before. None of the individuals 
had a history of internal systemic disease, pelvic-ovarian sur-
gery, or familial breast/ovarian cancer. Informed consent was 
obtained from all the patients and controls. This study was 
approved by Baskent University Institutional Review Board and 
Ethics Committee (Project No: KA13/297) and was supported 
by Baskent University Research Fund and Turkish German 
Gynecology Education and Research Foundation.
Next-generation sequencing analyses
Genomic DNA was obtained from 200 µL peripheral blood 
samples from each individual using the QIAamp DNA Blood 
Mini Kit (Qiagen Inc.; Hilden, Germany) according to the manu-
facturer’s instructions.
Primer design was performed for the coding regions of BRCA1 
and BRCA2 genes. These primers were used to construct a 
library containing the essential nucleotide sequences. Thirty-
eight primers for BRCA1 and 40 for BRCA2 were used to amplify 
19 and 20 amplicons, respectively. The sizes of the amplicons 
varied between 299 and 5504 bps. PCRs were performed on 
isolated DNA samples, using the designed primers, and the 
reactions were checked by 2% agarose gel electrophoresis. 
PCRs belonging to each individual were mixed to obtain PCR 
pools, which had all the amplicons of each individual in one 
tube. While mixing, the amplification efficiency and the length 
of the amplicons were taken into consideration; the volume for 
each PCR was directly proportional to the length of the ampli-
con and inversely proportional to the efficiency of the reaction, 
which was estimated by gel electrophoresis. The PCR pools for 
each individual were purified using the NucleoFast® 96 PCR 
kit (MACHEREY-NAGEL GmbH; Düren, Germany). The purified 
pools were quantified using a ND1000 (Thermo Fisher Scientific 
Inc.; Wilmington, DE, USA) micro volume spectrophotom-
eter and standardized to 0.2 ng/μL, which was needed for the 
sample preparation step. The samples were prepared for next-
gene sequencing using the NexteraXT sample preparation kit 
(Illumina Inc.; San Diego, CA, USA). Sequencing was performed 
using the Next Generation Sequencing MiSeq Illumina sequenc-
er (Illumina Inc.; San Diego, CA, USA). Obtained sequences 
were aligned to the reference genome (GRCh37/hg19) using 
MiSeq Reporter software (Illumina Inc.; San Diego, CA, USA).
Analysis of the variants
The data were analyzed on IGV 2.3 software (Broad Institute; 
Cambridge, MA, USA). The clinical outcomes of the variations 
found on the samples were estimated using the following 
databases: Ensembl (http://www.ensembl.org/index.html) and 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) for minor allele 
frequencies; SIFT (http://sift.jcvi.org/), Mutation Taster (http://
www.mutationtaster.org/), and Polyphen II (http://genetics.
bwh.harvard.edu/pph2/) for the effects of amino acid changes 
on the protein; HSF (http://www.umd.be/HSF3/) for the muta-
tions that affect the splicing pattern.
The established variants were cross-checked with Align GVGD 
(http://agvgd.iarc.fr/) and the breast cancer databases UMD-
BRCA1/BRCA2 (http://www.umd.be/BRCA1/, and http://www.
umd.be/BRCA2/).
Statistical analysis
To examine the association between BRCA variations and POI, 
Fisher’s-Exact Test and Student’s t-test were used. The outcome 
was considered statistically significant when the p value was 
below 0.05.
Results
Of the 101 women included in our study, 56 were in the study 
group and 45 in the control group. The mean ages were 33.4 
years (±4.5) and 29.4 years (±6.1), respectively. The difference 
in ages between the control and study groups was statistically 
significant. The mean E2 level in the study group was 52.3 pg/
mL (±82.1), and the FSH level was 23.1 IU/mL (±10.1).
Next-generation analysis results
We identified a total of 11 BRCA1 and 13 BRCA2 sequence 
variants in the study group. Two of the variants detected in 
the study group have not been reported in the BIC and UMD-
BRCA1/BRCA2 databases previously. Of these novel variants, 
c.3737C>A was in BRCA1 and c.9934A>G were in BRCA2 
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Table 1. Variants in the BRCA1 and BRCA2 genes in the study and control groups
         Control group 
          % (n:45)/
   SIFT Variation class Polyphen– Polyphen–   Study group  
Exon cDNA Protein (0-1)  (UMD) HumDiv HumVar GVGD Domain % (n:56)
BRCA1
7 c.536A>G p.Y179C 0 1 - 0.85 Class45 - 2 (1)/0 (0)
10 c.1067A>G p.Q356R - 1 - - Class0 BRCTassoc 16 (7)/14 (8)
10 c.2077G>A p.D693N - 1 - - Class0 EIN3 20 (9)/9 (5)
10 c.2612C>T p.P871L - 1 - - Class0 EIN3 67 (30)/55 (31)
10 c.3113A>G p.E1038G - 1 - - Class0 - 60 (27)/54 (30)
10 c.3119G>A p.S1040N - 1 0.01 - Class0 - 2 (1)/2 (1)
10 c.3541G>A p.V1181I 0.26 1 - 0.01 Class0 - 0 (0)/2 (1)
10 c.3548A>G p.K1183R - 1 - - Class0 - 62 (27)/54 (30)
10 c.3737C>A p.T1246N 0 Not reported - - Class0 - 0 (0)/2 (1)
10 c.1456T>C p.F486L 0.22 - - -  BRCTassoc 2 (1)/0 (0)
10 c.1648A>C p.N550H 0.01 - 0.99 0.88  - 2 (1)/0 (0)
12 c.4342A>G p.S1448G 0.01 3 0.33 - Class0 - 0 (0)/2 (1)
14 c.4535G>T p.S1512I 0.01 1 - 0.13 Class0 - 2 (1)/0 (0)
15 c.4837A<G p.S1613G - 1 - - Class0 - 64 (29)/54 (30)
15 c.4883T>C p.M1628T - 1 - - Class0 - 2 (1)/0 (0)
15 c.4956G>A p.M1652I - 1 - - Class0 BRCT 4 (2)/2 (1)
23 c.5504G>A p.R1835Q 0.02 Not reported BRCT domain - Class0 BRCT 2 (1)/0 (0)
BRCA2
3 IVS2-7T>A - - Not reported - - - - 2 (1)/0 (0)
10 c.865A>C p.N289H - 1 - - Class0 - 9 (4)/13 (7)
10 c.1114A>C p.N372H - 1 - - - - 47 (19)/45 (26)
10 c.1368G>C p.E456D 0.04 - 0.85 0.32 Class0 - 2 (1)/0 (0)
11 c.2971A>G p.N991D - 1 - - Class0 - 9 (4)/11 (6)
11 c.5744C>T p.T1915M - 1 - - Class0 - 4 (2)/4 (2)
11 c.4258G>T p.D1420Y 0 1 0.03 0.01 - - 4 (2)/2 (1)
11 c.6853A>G p.I2285V 0.12 2 0.61 0.14 Class25 - 0 (0)/2 (1)
11 c.6100C>T p.R2034C - 1 - - Class0 - 0 (0)/2 (1)
11 c.3318C>G p.S1106R 0 - 1 1 - - 2 (1)/0 (0)
11 c.2919G>A p.S973S - - - - - - 2 (1)/0 (0)
18 c.8187G>T p.K2729N 0.07 3 1 0.93 Class35 BRCA2DBD_OB1 2 (1)/2 (1)
22 c.8851G>A p.A2951T - 1 - - Class55 BRCA2DBD_OB2 2 (1)/4 (2)
26 c.9581C>A p.C3194Q 0.12 3 1 0.95 - - 0 (0)/2 (1)
27 c.9934A>G p.I3312V 0.88 Not reported 0 0 Class0 - 0 (0)/2 (1)
27 c.10234A>G p.I3412V - 1 - - Class0 - 0 (0)/2 (1)
27 c.9976A>T p.K3326X - 1 - - - - 4 (2)/2 (1)
Classification UMD database: 1 - Neutral, 2 - likely neutral or contradictory neutral/UV, 3 - UV, 4 - likely causal or contradictory deleterious/UV, 5 - 
Causal. Neutral variant: non-causal variant in terms of disease risk, present in less than 1% of the general population, designated as “less likely” for 
Align-GVGD, “benign” for PolyPhen, and “not clinically important” for BIC. Polymorphism: neutral variant present in more than 1% of the general 
population, Predicted neutral: considerable evidence for neutrality but no final GGC decision. UV: unclassified variant, designated as “unknown” for 
BIC. Predicted causal: considerable evidence for pathogenicity but no final GGC decision, Causal mutation: causal or pathogenic mutation in terms of 
disease risk, designated as “most likely” for Align-GVGD, “damaging” for PolyPhen, “pathogenic” for UMD-Predictor, and “clinically important” for BIC
PolyPhen results for each variant were classified as benign (score ≤0.5), possibly damaging (0.5< score <2), probably damaging (score >2), and unknown. 
C/P: P: Patient group; C: Control group, patient numbers with * indicates homozygous variant, patient number without * indicates heterozygote variant.
SIFT score: Ranges from 0 to 1. The amino acid substitution is predicted damaging is the score is <=0.05, and tolerated if the score is >0.05. 
GVGD: Align GVGD scores amino acid substitutions on a 7-scale scoring system, from C0 to C65. C0: Neutral, C15-25 intermediate, as changes to 
protein structure or function are uncertain, and C35 scores or higher are considered as likely deleterious.
UMD: Universal Mutation Database; SIFT: Sorting Tolerant From Intolerant; GVGD: Grantham Variation Grantham Deviation; BIC: Breast Cancer Infor-
mation Core; BRCT: BRCA C-terminus
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genes. In contrast, in the control group, 14 BRCA1 and 12 BRCA2 
sequence variants were detected. Two of them were novel: 
c.5504G>A in BRCA1 and IVS2-7T>A in BRCA2 genes. All the 
detected variants are shown in Table 1.
Each BRCA1 variant was seen in different numbers of individu-
als (Table 1). For example, c.4342A>G was seen only in one 
individual in the study group. However, c.3113A>G was seen in 
27 individuals in the control group and in 30 individuals in the 
study group. BRCA2 variants were also seen in different num-
bers of individuals in each group. As an example, c.1368C>G 
was seen in only one individual in the control group; however, 
c.1114A>C was detected in 19 individuals in the control group 
and in 20 individuals in the study group.
Discussion
According to the best of our knowledge, this study was the first 
to perform BRCA1 and BRCA2 gene sequencing using next-gen-
eration sequencing methods in Turkish patients with premature 
ovarian insufficiency. Different variants were detected in BRCA1 
and BRCA2 genes.
There are only a few relevant studies in the literature investigat-
ing the relationship between BRCA1 and BRCA2 mutations and 
premature ovarian failure and/or ovarian reserve or ovarian 
stimulation (3–5,11). For the first time, Oktay et al. (4) showed 
the relationship between ovarian stimulation and BRCA1 muta-
tions and concluded that there might be a possible link 
between gene repair and infertility and breast/ovarian cancer 
risks. Then, Titus et al. (11) showed the association between 
BRCA1-related DNA double-strand break repair and ovarian 
aging in mice and humans. Finch et al. (3) found that women 
carrying a BRCA mutation experience menopause earlier, on 
average, than women who have no mutations, although the 
difference is small and does not affect fertility. Santoro (12) 
commented on Finch et al.’s (3) study that BRCA mutations 
appear to have normal fertility in a study group. A recent study 
concluded that BRCA1 germ-line mutations may be associated 
with reserved ovarian reserve (5). Another study investigated 
the effects of BRCA1 and BRCA2 mutations on female infertil-
ity (13). Finally, a recent study (14) reported that patients with 
BRCA gene mutations showed a normal ovarian response in 
IVF compared to patients with no BRCA mutations. A survey 
reported that knowledge of BRCA mutations affects the mar-
riage and childbearing decisions of the patients (15). However, 
most of the studies used different study groups from our study, 
with other studies mostly including patients who had IVF treat-
ment with BRCA1 and BRCA2 mutations (14), whereas our 
study group consisted of women diagnosed with POI.
BRCA1 encodes an 1863 amino acid protein. It has three major 
domains: first, the N-terminal RING finger (amino acids 18–136); 
second, consisting of three nuclear localization signals in the 
central region; and third, the tandem of two BRCA1 C-terminus 
(BRCT) domains (i.e., BRCT1: amino acids 1642–1736; BRCT2, 
amino acids 1756–1835) at the C-terminus (16). Many inherited 
cancer-associated BRCA1 mutations have been found within 
the RING and BRCT domains, indicating that both domains are 
involved in suppressing breast and ovarian cancer (17).
We detected two variations in BRCA1 and two in BRCA2 that 
have not been reported before. The first one in BRCA1 was 
p.T1246N and was detected only in one patient with POI but 
was not detected in the control group. Although it does not 
correspond to any domain, the SIFT score was 0, which means 
the amino acid substitution can be predicted to be damaging. 
The GVGD score shows that amino acid substitution is not 
deleterious. However, our results are not sufficient to conclude 
whether the variation involves a polymorphism.
The other variation detected in BRCA1 was p.R1835Q, which 
corresponds to the BRCT domain and was seen in only one 
individual in the control group but none in the study group. 
According to the SIFT score of 0.02, the amino acid substitution 
can be predicted to be damaging. The BRCT (BRCA1 carboxyl 
terminal domain) domain is an evolutionary conserved module 
that exists in a large number of proteins, from prokaryotes to 
eukaryotes. Most of the proteins that contain the BRCT domain 
participate in DNA damage checkpoint or DNA repair pathways. 
However, the function of the domain is still controversial. It is 
known that germ-line mutations in the BRCT domain lead to 
50% of familial breast cancers (18). Most BRCT domain muta-
tions cause a truncated BRCA1 protein. It has been shown that 
loss of the BRCT domain leads to tumor formation in mice 
(19). Therefore, the BRCT domain has an important role in the 
cellular process of DNA damage. Because BRCT repeats are 
found in different proteins associated with the regulation of the 
DNA damage response, such as BARD1, 53BP1, and MDC1, this 
individual in the control group did not show any clinical signs 
although she had the mutation in the BRCT domain. Other 
proteins that have a BRCT domain might function properly to 
protect tumor formation in this individual. The risk of develop-
ing breast cancer by the age of 70 years for BRCA1 mutation 
carriers is between 57% and 65% and between 45% and 57% for 
BRCA2. The risk of developing ovarian cancer by the age of 70 
years for BRCA1 mutation carriers is between 39% and 59% and 
between 11% and 18% for BRCA2. However, the overall risk for 
younger age (<40) is reported to be lower for ovarian cancer 
in BRCA1 and BRCA2 mutation carriers (20-22). It is also known 
that BRCA mutations in oocytes may lead to early depletion of 
the ovarian reserve (4). There are also other factors that affect 
breast-ovarian cancer, such as age, gender, family history of 
breast-ovarian cancer, and mutations other than BRCA1 and/or 
BRCA2 genes (ATM, TP53, CHEK2, PTEN, CDH1, STK11, PALB2) 
(23). Because we did not have other clinical data, such as fam-
ily history or mutations in other genes of this individual, it was 
not possible to predict the clinical outcome.
We detected two new variations in BRCA2. The first one was in 
the intergenic sequence IVS-7T>A, which was detected only in 
one patient in the control group but none in the study group. 
Because the intergenic sequence is a non-coding region, there 
might not be an effect on a gene or a protein, thus resulting 
in no clinical signs in the patient. The second new variation 
p.I3312V was detected in only one case in the study group 
(1/45). The SIFT score was 0.88, which means that the amino 
acid substitution is tolerated. Although the new variation was 
detected in a patient with POI, this might not be related with 
the disease because the amino acid substitution is tolerated 
J Turk Ger Gynecol Assoc 2016; 17: 77-82
Karakaş Yılmaz et al.
BRCA1 and BRCA2 variations in patients with POI80
and does not correspond to any domain. Therefore, the varia-
tion might be only a rare polymorphism seen in the Turkish 
population.
We detected 17 different variations in BRCA1 and 17 in BRCA2. 
Six of 17 BRCA1 variations corresponded to a domain, whereas 
only 2 of 17 variations corresponded to a domain in BRCA2. 
Oktay et al. (4) found nine variations in BRCA1 and BRCA2 
that might be associated with premature ovarian failure and/
or ovarian reserve. Of those, only one of them corresponded 
to the BRCT domain; however, another five variations did not 
correspond to any domain. Wang et al. (5) detected 13 different 
variations in BRCA1 and 10 in BRCA2. Five of them correspond 
to BRCA domains. Of them, only one corresponded to the BRCT 
domain.
Our study has a limited number of individuals in both the study 
and control groups. In addition, our study lacks the confirma-
tion of the detected variations by Sanger sequencing. However, 
the depth of coverage of our study was >100x in 98% of the 
patients. We repeated the results when the depth of coverage 
was <20x. Current next-generation sequencing guidelines for 
inherited disorders do not define quality parameters to provide 
concrete guidance for confirmatory analysis. In a recent next-
generation sequencing laboratory standards paper, the College 
of American Pathologists justifies that “Sufficient depth of 
coverage and quality parameters should not expect false posi-
tives in their filtered data” (24). Implementing NGS-based tests 
according to diagnostic standards is a challenge for individual 
laboratories. To facilitate the implementation of NGS into rou-
tine laboratory practice several studies done such as the Dutch 
Society for Clinical Genetic Laboratory Diagnostics (VKGL) 
working group. And also, in a recent paper researchers have 
been emphasized that the necessity of Sanger confirmation of 
next-generation sequencing variants lower than 30x depth of 
coverage might need to be explored (25).
As a conclusion, we did not detect an association between POI 
and the BRCA1 and BRCA2 gene variations. However, functional 
studies are needed to clarify the variations of BRCA1 and BRCA2 
genes because there are conflicting results about the associa-
tion of BRCA1 and BRCA2 variations. In case of detecting varia-
tions that are related to breast-ovarian cancer, these patients 
might be referred for screening and follow-up programs for 
breast-ovarian cancer before they reach the age of 40 years. We 
also detected new variations in BRCA1 and BRCA2 genes both 
in the study and control group, which have not been reported 
before. Therefore, next-generation sequencing is a valuable 
tool to detect gene variations of large genes in a fast and cost-
effective way.
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